Bring Down Triglycerides with Bezalip Bezafibrate Sustained-Release Drug Part 3

Risk to Liver Function

Generic Bezalip (Bezafibrate) may impede the functioning of liver, ascertained by liver function tests inside 6 months of commencing treatment and then every year. It is believed that Generic Bezalip is broken down by the metabolic process of the liver; therefore it is not advised with liver disorder excluding fatty liver (commonly marked with elevated cholesterol). Symptoms of liver ailment comprise failing, weariness, irritation in abdomen and jaundice (yellowing of the skin and the whites of the eyes). Generic Bezalip administered in conjunction with MAO (monoamine oxidase) inhibitors may also lead to liver impairment.